Capecitabine (Xeloda) Archives

Tag: Capecitabine (Xeloda)

Chemotherapy agent often used to treat well differentiated Neuroendocrine Tumours, often as a combination therapy with Temozolomide (Temodal). In combo this is known as CAPTEM.

A drug used to treat stage III colorectal cancer that was removed by surgery and colorectal cancer that has spread to other parts of the body. It is also used to treat breast cancer that has spread to other parts of the body and has not gotten better after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Capecitabine is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills cancer cells. Capecitabine is a type of antimetabolite. Also called Xeloda.

21 Apr 2024

By Ronny Allan

9 Comments

Chemotherapy for Neuroendocrine Neoplasms

Treatment5-Fluorouracil (5-FU), Afinitor, Cancer research, Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, Carboplatin, Chemotherapy, Cisplatin, Etoposide, Everolimus, FCarboSt, FOLFIRI, FOLFOX, High Grade NEC, Irinotecan (Campto), Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Paclitaxel (Taxol), Poorly differentiated, PRRT, Somatostatin analogues, Streptozotocin (Zanosar), Sunitinib (Sutent), Temozolomide (Temodal), Vepesid), Well differentiated, XELOX. Oxaliplatin (Eloxatin)

By Ronny Allan – Living with Neuroendocrine Cancer Chemotherapy has a long and complicated history in the management of Neuroendocrine Neoplasms (NENs) (an umbrella term for both Neuroendocrine Tumours (NET) and Neuroendocrine Carcinomas (NEC)). Unlike many other cancers, most well‑differentiated NETs are relatively resistant to traditional cytotoxic chemotherapy. However, chemotherapy remains an important option for specific subtypes, particularly higher‑grade disease, and certain anatomical sites. There's a myth that circulates the NET patient groups along the lines of "chemotherapy does not work for NETs". That's not entirely true or at best totally out of context. However, it's true to say that…

15 Jun 2022

By Ronny Allan

0 Comments

CAPTEM for Neuroendocrine Tumours

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, Chemotherapy, Clinical trial, Pancreatic NET (PanNET), Temozolomide (Temodal)

What is CAPTEM? Capecitabine is an oral drug used alone or with other drugs to treat certain types of colorectal cancer and breast cancer. It is also being studied in the treatment of other types of cancer including in combination with a second drug. Capecitabine is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Also called Xeloda. Note -Capecitabine is an oral Oral 5-FU prodrugs which are medications designed to be taken by mouth and converted into the active chemotherapy agent 5-flourouracil (5-FU) within the body, aiming for higher tumour selectivity and…

07 Mar 2021

By Ronny Allan

0 Comments

Treatment for Neuroendocrine Cancer – a summary for patients

Treatment5-Fluorouracil (5-FU), Atezolizumab (Tecentriq), Avelumab (Bavencio), Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., Chemotherapy, Cisplatin, Cisplatin/Etoposide, Cryoablation, Cyberknife, Etoposide, External beam radiotherapy, FOLFIRI, FOLFOX, Gamma knife, Interferon alpha (IFNα), Irinotecan (Campto), Irreversible electroporation (IRE), Lanreotide, Liver directed therapy, Lu-177, Lutathera, NanoKnife®, Nivolumab (Opdivo), Octreotide (Octreotide acetate), Opdivo (Nivolumab), Paclitaxel (Taxol), Pembrolizumab (Keytruda), Peptide receptor radionuclide therapy (PRRT), Proton beam therapy, Radiation therapy, Somatostatin analogues, Somatostatin receptors (SSTR), Somatuline Autogel (US: depot), Stereotactic body radiotherapy (SBRT), Stereotactic radiosurgery (SRS), Streptozotocin (Zanosar), Surgery, Targeted therapy, Temozolomide (Temodal), Thorson-Bioerck syndrome, Tumour mutational burden (TMB), Vepesid), Watchful waiting

1. Scope This summary provides an overview of the types of therapy known for treating Neuroendocrine Cancer. They will have been approved at least by one national or regional approval agency, may not be available or approved in your own country; and may appear in clinical guidelines for the treatment of Neuroendocrine Cancer. Clinical trials will not be covered, although it's noted that some of the approved treatments listed may be in follow on trials either to prove new coverage or used in combination with another drug. For a list of clinical trials covered by the author, click here.…

20 May 2016

By Ronny Allan

0 Comments

Clinical Trial: PRRT and CAPTEM combination therapy

Clinical Trials and ResearchCapecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, CONTROLNETS, Peptide receptor radionuclide therapy (PRRT), PRCRT, PRRT, Temozolomide (Temodal)

Updated 2026: A more recent, mature publication from the same Australian CONTROL NET programme has confirmed the earlier signal: combining PRRT with CAPTEM produces high response rates, particularly in pancreatic NETs, but at the cost of substantially increased haematologic toxicity and no clear, durable survival advantage strong enough to change guidelines. Highlights Efficacy outcomes from PRRT+CAPTEM in NENs remain unclear. PRRT/CAPTEM was feasible and well tolerated in this randomized trial. SBNETS: No PFS difference between PRRT/CAPTEM and PRRT. PNETs: PFS/ORR for PRRT/CAPTEM numerically higher than CAPTEM on extended follow-up. Randomized studies in uncommon tumours are essential to optimise practice. Interesting…